

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Zoon *et al.*

**Patent No.** 7,235,232

**Issued:** June 26, 2007

**Application No.** 10/615,723

**Filed:** July 8, 2003

**Confirmation No.** 9429

**FILED VIA EFS**

**For:** INTERFERON ALPHA HYBRIDS

**Examiner:** Jegatheesan Seharaseyon

**Art Unit:** 1647

**Attorney Reference No.** 4239-64129-01

FILED VIA EFS

UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR CERTIFICATE OF CORRECTION

The following printing errors were noted in comparing the printed patent with the papers in the attorneys' files:

On the Cover:

In (56) OTHER PUBLICATIONS, Fidler et al., "tomor" should be --tumor--.

In the Specification:

Column 1, Line 13, "entirely" should be --entirety--.

Column 3, Line 65, "interferon- $\alpha$  xs, and" should be --interferon- $\alpha$ s, and--.

Column 4, Line 6, "as well to modulate" should be --as well as to modulate--.

Column 4, Line 13, "IFN- $\alpha$ -21b" should be --IFN- $\alpha$ 21b --.

Column 5, Line 1, "IFN $\alpha$ 2c" should be --IFN- $\alpha$ 2c--.

Column 5, Line 9, "IFN' $\alpha$ s." should be --IFN- $\alpha$ s.--.

Column 5, Line 37, "interferon  $\alpha$ 21b" should be --interferon- $\alpha$ 21b--.

Column 5, Line 38, "interferon- $\alpha$  2c" should be --interferon- $\alpha$ 2c--.

Column 5, Line 38, "0" should be --"O"--.

Column 5, Line 39, “interferon- $\alpha$  21b” should be --interferon- $\alpha$ 21b--.

Column 5, Line 40, “interferon- $\alpha$  2c” should be --interferon- $\alpha$ 2c--.

Column 6, Line 67, “IFN- $\alpha$ 21 b” should be --IFN- $\alpha$ 21b--.

Column 7, Line 2, “IFN- $\alpha$ 21 b” should be --IFN- $\alpha$ 21b--.

Column 8, Line 10, “HY-5 SEQ” should be --HY-5. SEQ--.

Column 9, Line 49, “interferon- $\alpha$  2c” should be --interferon- $\alpha$ 2c--.

Column 9, Line 51, “interferon- $\alpha$  2c.” should be --interferon- $\alpha$ 2c.--.

Column 10, Line 34, “IFN-  $\alpha$ -21b” should be --IFN- $\alpha$ 21b--.

Column 15, Line 15, “IFN- $\alpha$ 21 b” should be --IFN- $\alpha$ 21b--.

Column 15, Line 48, “and 6” should be --and -6--.

Column 15, Line 55, “IFN- $\alpha$ c21b” should be --IFN- $\alpha$ 21b--.

Column 15, Line 56, “HY 4” should be --HY-4--.

Column 15, Line 57, “14 as” should be --14as--.

Column 15, Line 63, “15 as” should --15as--.

Column 16, Line 23, “SDM1 as” should be --SDM1as--.

Column 16, Line 30, “SDM2 as” should be --SDM2as--.

Column 16, Line 36, “SDM3 as” should be --SDM3as--.

Column 16, Line 42, “SDM4 as” should be --SDM4as--.

Column 17, Line 35, “the manufactures” should be --the manufacturers--.

Column 17, Line 40, “IFNA-b 2” should be --IFNA2--.

Column 18, Lines 6-7, “purification of may” should be --purification may --.

Column 18, Line 25, “1997)” should be --1997).--.

Column 18, Line 63, “Bethesda Md.” should be --Bethesda, MD.--.

Column 20, Line 2, “with or without with” should be --with or without--.

Column 20, Line 10, “preformed” should be --performed--.

Column 20, Line 17, “1982” should be --1992--.

Column 21, Line 1, “IFN- $\alpha$ ” should be --IFN- $\alpha$ X--.

Column 22, Line 10, “interferon  $\alpha$ 21b” should be --interferon- $\alpha$ 21b--.

Column 22, Line 13, “interferon- $\alpha$  21b” should be --interferon- $\alpha$ 21b--.

Column 22, Line 14, “interferon- $\alpha$  2c.” should be --interferon- $\alpha$ 2c--.

Column 23, Line 35, “polyakylene” should be --polyalkylene--.

Column 24, Table 1, Header, “(ng/ml)<sup>8</sup>” should be --(ng/ml)<sup>a</sup>--.

Column 24, Table 1, Column 1, “IFN- $\alpha$ 21a” should be --IFN- $\alpha$ 21b--.

Column 25, Table 1, Column 2, “NID” should be --N/D--.

Column 24, Table 1, Legend, “<sup>128</sup>I-IFN- $\alpha$ 2b” should be --<sup>125</sup>I-IFN- $\alpha$ 2b--.

In the Sequence Listing:

SEQ ID NOs: 43 and 44 (*see* the replacement Sequence Listing submitted November 10, 2006) are missing from the Sequence Listing in the patent. The following text is missing from the Sequence Listing:

```
<210> SEQ ID NO 43
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (5)..(5)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9)..(9)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 43
```

```
Leu Asp Lys Phe Xaa Thr Glu Leu Xaa Gln Gln Leu Asn Asp
1           5           10
```

```
<210> SEQ ID NO 44
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (5)..(5)
```

<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (9)..(9)  
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid  
  
<400> SEQUENCE: 44

Leu Glu Lys Phe Xaa Thr Glu Leu Xaa Gln Gln Leu Asn Asp  
1 5 10

In the Claims:

Column 59, Line 44, “interferon $\alpha$ ” should be --interferon- $\alpha$ --.

Column 59, Line 64 to Column 60, Line 19, “wherein the second amino acid sequence consists of residues wherein the second amino acid sequence consists of residues 76-81” should be --wherein the second amino acid sequence consists of residues 76-81--.

Column 60, Line 37, “wherein the second amino acid sequence consists of residues wherein the second amino acid sequence consists of 76-81” should be --wherein the second amino acid sequence consists of 76-81--.

Since not all of the above errors are attributable to the Patent Office, the fee of \$100.00 pursuant to 37 C.F.R. 1.20(a). is submitted herewith. The preceding corrections remedy mistakes of a typographical nature and/or minor character. The Certificate of Correction is enclosed to make formal notice of the errors in the referenced patent.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Tanya M. Harding/  
Tanya M. Harding, Ph.D.  
Registration No. 42,630

cc: Docketing